Guangdong Hybribio BiotechLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jianyu Wang

Chief executive officer

CN¥6.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	1.7yrs
CEO ownership	n/a
Management average tenure	6.6yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO

Jianyu Wang (62 yo)

1.7yrs

Tenure

CN¥6,109,300

Compensation

Ms. Jianyu Wang is the General Manager at Guangdong Hybribio Biotech Co.,Ltd. since August 31, 2022 and was its Executive Deputy General Manager until August 31, 2022. She has been Director at Guangdong Hy...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jianyu Wang	GM & Director	1.7yrs	CN¥6.11m	no data
Qinghui Li	Finance Director	10yrs	CN¥953.10k	0.0071% CN¥ 282.7k
Longxu Xie	Deputy GM & Director	13.6yrs	CN¥1.46m	0.059% CN¥ 2.3m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	no data	CN¥9.39m	0.57% CN¥ 22.6m
Yi Chen	Deputy GM & Board Secretary	no data	CN¥918.20k	0.013% CN¥ 502.9k
Danrong Weng	Deputy General Manager	3.3yrs	CN¥1.03m	0.0056% CN¥ 219.8k

6.6yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 300639's management team is seasoned and experienced (6.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jianyu Wang	GM & Director	7.6yrs	CN¥6.11m	no data
Longxu Xie	Deputy GM & Director	3.5yrs	CN¥1.46m	0.059% CN¥ 2.3m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	13.6yrs	CN¥9.39m	0.57% CN¥ 22.6m
Meilan Qiu	Supervisor	6.8yrs	no data	no data
Weixiong Huang	Vice Chairman of the Board	13.6yrs	CN¥300.00k	no data
Xiaoyan Yang	Director	13.6yrs	CN¥120.00k	no data
Qiaozhong Guan	Chairman of the Board	13.6yrs	CN¥3.74m	no data
Wanjian Xu	Employee Representative Supervisor	10.7yrs	no data	no data
Ruijun Ma	Chairman of the Supervisory Board	4.6yrs	no data	no data
Youlin Qiao	Independent Director	1.7yrs	CN¥40.00k	no data
Chunxue Yang	Independent Director	1.7yrs	CN¥40.00k	no data
Yingshi Chen	Independent Director	1.7yrs	CN¥40.00k	no data

7.2yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 300639's board of directors are considered experienced (7.2 years average tenure).

Guangdong Hybribio BiotechLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 24% overvalued

Guangdong Hybribio Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorates as stock falls 16%

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: EPS: CN¥0.076 (vs CN¥0.78 in 3Q 2022)

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.73 in 2Q 2022)

Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on October 10, 2022.

Third quarter 2022 earnings released: EPS: CN¥1.17 (vs CN¥0.59 in 3Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Second quarter 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.50 in 2Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2021, Payable on April 29, 2022

Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd. Announces Final Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Now 22% undervalued

Investor sentiment improved over the past week

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.88 (vs CN¥0.54 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.75 (vs CN¥0.43 in 2Q 2020)

Investor sentiment improved over the past week

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2020, Payable on May 28, 2021

Guangdong Hybribio Biotech Co.,Ltd. Approves Profit Distribution for 2020

First quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.09 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.70 in FY 2019)

New 90-day low: CN¥32.33

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥33.91

Investor sentiment deteriorated over the past week

New 90-day low: CN¥42.94

Third quarter earnings released

Third quarter earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age